Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
Benaboud S, Solas C, Bouchet S, Gregoire M, Lemaitre F, Venisse N, Lê MP, Muret P, Parant F, Neant N, Boujafaar S, Lagoutte-Renosi J, Garraffo R, Peytavin G. Benaboud S, et al. Among authors: venisse n. J Antimicrob Chemother. 2023 Mar 2;78(3):853-854. doi: 10.1093/jac/dkad009. J Antimicrob Chemother. 2023. PMID: 36683308 No abstract available.
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
Venisse N, Peytavin G, Bouchet S, Gagnieu MC, Garraffo R, Guilhaumou R, Solas C; ANRS-AC43 Clinical Pharmacology Committee, SFPT Therapeutic Drug Monitoring and Treatment Personalization group. Venisse N, et al. Antiviral Res. 2020 Sep;181:104866. doi: 10.1016/j.antiviral.2020.104866. Epub 2020 Jul 10. Antiviral Res. 2020. PMID: 32659293 Free PMC article. Review.
Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1-infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER study).
Lemaitre F, Lagoutte-Renosi J, Gagnieu MC, Parant F, Venisse N, Grégoire M, Bouchet S, Garraffo R, Lê MP, Muret P, Comets E, Solas C, Peytavin G; ANRS-MIE-BIRIDER Study group on behalf of the Clinical Pharmacology Group of ANRS-MIE AC43. Lemaitre F, et al. Among authors: venisse n. Br J Clin Pharmacol. 2024 Jan;90(1):264-273. doi: 10.1111/bcp.15890. Epub 2023 Sep 18. Br J Clin Pharmacol. 2024. PMID: 37602480 Free article.
Preparation and stability of voriconazole eye drop solution.
Dupuis A, Tournier N, Le Moal G, Venisse N. Dupuis A, et al. Among authors: venisse n. Antimicrob Agents Chemother. 2009 Feb;53(2):798-9. doi: 10.1128/AAC.01126-08. Epub 2008 Nov 10. Antimicrob Agents Chemother. 2009. PMID: 19001119 Free PMC article.
Plasma exchange significantly affects darunavir exposure.
Garcia M, Le Moal G, Dupuis A, Rochette N, Roblot F, Venisse N. Garcia M, et al. Among authors: venisse n. J Antimicrob Chemother. 2014 Aug;69(8):2296-7. doi: 10.1093/jac/dku108. Epub 2014 Apr 10. J Antimicrob Chemother. 2014. PMID: 24722841 No abstract available.
60 results